Pomalidomide for the treatment of relapsed and refractory multiple myeloma

Bibliography

• Palumbo A, Cerrato C. Diagnosis and therapy of multiple myeloma. Korean J Intern Med 2013;28(3):263-73
   PubMed Web of Science ®Google Scholar
• Bird JM, Owen RG, D’Sa S, et al. Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154(1):32-75
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009;94(2):270-5
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516-20
   PubMed Web of Science ®Google Scholar
• Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011;117(11):3025-31
   PubMed Web of Science ®Google Scholar
• Yang B, Yu RL, Chi XH, Lu XC. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One 2013;8(5):e64354
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906-17
   PubMed Web of Science ®Google Scholar
• Zeng Z, Lin J, Chen J. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Ann Hematol 2013;92(7):935-43
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352(24):2487-98
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133-42
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26(1):149-57
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24(1):22-32
   PubMed Web of Science ®Google Scholar
• Castelli R, Cannavò A, Conforti F, et al. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacol Immunotoxicol 2012;34(5):740-53
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96(9):2943-50
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99(12):4525-30
   PubMed Web of Science ®Google Scholar
• San Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(11):1055-66
   PubMed Web of Science ®Google Scholar
• Rychack L, Mendy D, Miller K, et al. Overcoming resistance; the use of pomalidomide (pom) and dexamethasone (dex) in re-sensitizing lenalidomide (Len)-resistant multiple myeloma cells. Haematologica (13th International Myeloma Workshop Abstracts) 2011;96(s1):S126
   Google Scholar
• Celgene Corp. Pomalyst® (pomalidomide) prescribing information. Summit, NJ, USA. 2014. Available from: http://www.pomalyst.com/wp-content/uploads/2013/08/prescribing_information.pdf
   Google Scholar
• Celgene Europe Ltd. Imnovid® (pomalidomide) summary of product characteristics. Uxbridge, UK. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002682/WC500147717.pdf
   Google Scholar
• Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 2013;160(5):649-59
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Jagannath S, et al. A phase II trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2014;123(10):1461-9
   PubMed Web of Science ®Google Scholar
• Sellner L, Heiss C, Benner A, et al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer 2013;119(13):2438-46
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120(14):2817-25
   PubMed Web of Science ®Google Scholar
• Wang M, Martin T, Bensinger W, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122(18):3122-8
   PubMed Web of Science ®Google Scholar
• Berenson JR, Hilger JD, Yellin O, et al. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia 2014;28(7):1529-36
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer E, Abonour R, et al. Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Blood 2013;122(21):690a
   Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4(4):314-22
   PubMed Web of Science ®Google Scholar
• Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 2004;4(12):1963-70
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69(18):7347-56
   PubMed Web of Science ®Google Scholar
• Kim J, Sif S, Jones B, et al. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity 1999;10(3):345-55
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11):2326-35
   PubMed Web of Science ®Google Scholar
• Görgün G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116(17):3227-37
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210-16
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Mendy D, Waldman M, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol 2014;164(2):233-44
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014;343(6168):305-9
   PubMed Web of Science ®Google Scholar
• Zhu YX, Kortuem M, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2013;54(4):683-7
   PubMed Web of Science ®Google Scholar
• Terpos E, Kanellias N, Christoulas D, et al. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther 2013;6:531-8
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380-6
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15(12):1950-61
   PubMed Web of Science ®Google Scholar
• Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006;107(8):3098-105
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Todryk SM, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002;168(10):4914-19
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128(2):192-203
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305(3):1222-32
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol 2014;164(6):811-21
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58(7):1033-45
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 2013;71(2):489-501
   PubMed Web of Science ®Google Scholar
• Kasserra C, Assaf M, Hoffmann M, et al. Evaluation of CYP450 and transporter-mediated drug-drug interaction potential of pomalidomide in healthy men and in vitro. Blood (ASH Annual Meeting Abstracts) 2013;122:1989
   PubMed Web of Science ®Google Scholar
• Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269-76
   PubMed Web of Science ®Google Scholar
• Gay F, Mina R, Troia R, Bringhen S. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opin Drug Metab Toxicol 2013;9(11):1517-27
   PubMed Web of Science ®Google Scholar
• Chen N, Wen L, Lau H, et al. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 2012;69(3):789-97
   PubMed Web of Science ®Google Scholar
• Varma MV, Feng B, Obach RS, et al. Physicochemical determinants of human renal clearance. J Med Chem 2009;52(15):4844-52
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013;121(11):1961-7
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141(1):41-51
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014;123(12):1826-32
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev Anticancer Ther 2005;5(5):759-66
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Niesvizky R. How lenalidomide is changing the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol 2013;88(Suppl 1):S23-35
   PubMedGoogle Scholar
• Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(30):5008-14
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010;24(11):1934-9
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118(11):2970-5
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Kumar SK, LaPlant BR, et al. Pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed myeloma: long term follow up and factors predicting outcome in 345 patients. Blood (ASH Annual Meeting Abstracts) 2012;120:201
   Web of Science ®Google Scholar
• Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003;121(5):768-71
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004;5(4):318-24
   PubMedGoogle Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: intergroupe Francophone du Myelome 2009-02. Blood 2013;121(11):1968-75
   PubMed Web of Science ®Google Scholar
• Sehgal K, Kocoglu MH, Deng Y, et al. Comparison of intermittent and continuous dosing regimens of pomalidomide in relapsed/refractory myeloma: results of a phase II randomized trial. Blood (ASH Annual Meeting Abstracts) 2013;122:3205
   Web of Science ®Google Scholar
• Dimopoulos M, Weisel K, Song K, et al. Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). Blood 2013;122(21):408a
   Web of Science ®Google Scholar
• Weisel K, San Miguel JF, Song KW, et al. MM-003 Phase 3 study of pomalidomide in combination with low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): POM + LoDEX is beneficial for elderly patients (> 65 years of age). Blood (ASH Annual Meeting Abstracts) 2013;122:3198
   Google Scholar
• Weisel KC, Dimopoulos MA, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). J Clin Oncol (ASCO Annual Meeting Abstracts) 2013;31(Suppl):8527
   Google Scholar
• San Miguel JF, Weisel K, Song KW, et al. Patient outcomes by prior therapies and depth of response: analysis of MM-003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). Blood (ASH Annual Meeting Abstracts) 2013;122:686
   Web of Science ®Google Scholar
• Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood 2013;122(16):2799-806
   PubMed Web of Science ®Google Scholar
• Baz R, Martin TG, Alsina M, et al. Pomalidomide (Pom) dexamethasone (D) with or without oral weekly cyclophosphamide (Cy) for lenalidomide refractory multiple myeloma (LRMM): a multicenter randomized phase II trial. Blood (ASH Annual Meeting Abstracts) 2013;122:3200
   Google Scholar
• Usmani SZ, Stratton K, Hansen E, et al. Final results of phase II study of pomalidomide (Pom) in GEP-defined high risk relapsed and refractory multiple myeloma (RRMM). Blood (ASH Annual Meeting Abstracts) 2013;122:3191
   Google Scholar
• Richardson P, Hofmeister C, Siegel D, et al. MM-005: a phase 1 trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). Blood 2013;122(21):1969a
   Web of Science ®Google Scholar
• Mikhael J, Roy V, Richardson P, et al. A phase I/II trial of pomalidomide, bortezomib and dexamethasone in patients with relpased or refractory multiple myeloma. Blood 2013;122(21):1940a
   Web of Science ®Google Scholar
• Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (biaxin [clarithromycin]/revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111(3):1101-9
   PubMed Web of Science ®Google Scholar
• Mark TM, Boyer A, Rossi AC, et al. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. Blood 2013;122(21):1955a
   Web of Science ®Google Scholar
• Berenson JR, Hilger JD, Klein L, et al. Pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma: results from a phase 1/2 trial. Blood 2013;122(21):3218a
   Web of Science ®Google Scholar
• Weill Medical College of Cornell University. Study of pomalidomide, dexamethasone, and romidepsin for rel/ref myeloma (Romi Poma). In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2013. Available from: http://clinicaltrials.gov/show/NCT01979276 NCT01979276 [Accessed February 2014]
   Google Scholar
• Novartis Corporation. Phase I trial of everolimus, pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2014. Available from: http://clinicaltrials.gov/show/NCT01889420 NCT01889420 [Accessed February 2014]
   Google Scholar
• Acetylon Pharmaceuticals. ACY-1215 in combination with pomalidomide and low-dose dex in relapsed-and-refractory multiple myeloma. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2013. Available from: http://clinicaltrials.gov/show/NCT01997840 NCT01997840; [Accessed February 2014]
   Google Scholar
• Onyx Pharmaceuticals. A study of oprozomib, pomalidomide, and dexamethasone in subjects with primary refractory or relapsed and refractory multiple myeloma. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2014. Available from: http://clinicaltrials.gov/show/NCT01999335 NCT01999335 [Accessed February 2014]
   Google Scholar
• Matous J, Siegel DSD, Duong HK, et al. MM-008 trial: pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI). J Clin Oncol (ASCO Annual Meeting Abstracts) 2013;31(Suppl):8585
   Google Scholar
• Siegel DS, Richardson PG, Baz R, et al. Pomalidomide (POM) with low-dose dexamethasone (LoDEX) in patients with relapsed and refractory multiple myeloma (RRMM): impact of renal function on patient outcomes. Blood (ASH Annual Meeting Abstracts) 2012b;120:4072
   PubMed Web of Science ®Google Scholar
• Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in relapsed or refactory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14). ASH, New Orleans, LA; 2013. p. a689
   Google Scholar
• Jagannath S, Hofmeister CC, Baz RC, et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis. J Clin Oncol 2013;13(Suppl):abstract 8532
   Google Scholar
• Zeldis JB, Carter TL, Knight RD, Hui J. Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans. Proc Natl Acad Sci USA 2013;110(50):E4819
   PubMed Web of Science ®Google Scholar
• Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011;9(4):653-63
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Zweegman S, et al. Secondary malignancies in elderly myeloma patients. Haematologica 13th International Myeloma Workshop Abstracts 2011;96(S1):S24
   PubMedGoogle Scholar
• Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012;119(12):2731-7
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119(12):2764-7
   PubMed Web of Science ®Google Scholar
• Song KW, Dimopoulos MA, Weisel K, et al. Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) improves health-related quality of life (HRQoL) versus high-dose dexamethasone (HiDEX) in relapsed refractory multiple myeloma (RRMM) patients enrolled in MM-003 phase 3 randomized trial. Blood (ASH Annual Meeting Abstracts) 2013;122:2939
   Web of Science ®Google Scholar
• University of Chicago. Carilzomib, pomalidomide, and dexamethasone in treating patients with relapsed or refractory multiple myeloma. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2014. Available from: http://clinicaltrials.gov/show/NCT01665794 NCT01665794 [Accessed February 2014]
   Google Scholar
• Alliance for Clinical Trials in Oncology. Pomalidomide and dexamethasone with or without ixazomib in treating patients with refractory multiple myeloma. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2014. Available from: http://clinicaltrials.gov/show/NCT02004275 NCT02004275 [Accessed February 2014]
   Google Scholar
• Duke University Medical Center. Bendamustine + pomalidomide + dex in R/R multiple myeloma. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2014. Available from: http://clinicaltrials.gov/show/NCT01754402 NCT01754402 [Accessed February 2014]
   Google Scholar
• University Hospital Tuebingen. Phase II multicenter, open-label, single arm clinical study of pomalidomide and dexamethasone and cyclophosphamide. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2014. Available from: http://clinicaltrials.gov/show/NCT02046915 NCT02046915 [Accessed February 2014]
   Google Scholar
• Janssen Research & Development. A study of JNJ-54767414 (HuMax CD38) (Anti-CD38 monoclonal antibody) in combination with backbone treatments for the treatment of patients with multiple myeloma. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2014. Available from: http://clinicaltrials.gov/show/NCT01998971 NCT01998971 [Accessed February 2014]
   Google Scholar
• M.D. Anderson Cancer Center. Pomalidomide and dexamethasone with growth factor support. In: ClinicalTrials.gov [Internet] National Library of Medicine (US), Bethesda (MD); 2014. Available from: http://clinicaltrials.gov/show/NCT01946152 NCT01946152 [Accessed February 2014]
   Google Scholar
• Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw 2007;5(2):149-62
   PubMedGoogle Scholar
• Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011;17(6):1264-77
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121(6):884-92
   PubMed Web of Science ®Google Scholar
• Nemec P, Zemanova Z, Kuglik P, et al. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma 2012;53(5):920-7
   PubMed Web of Science ®Google Scholar
• Laubach JP, Mahindra A, Mitsiades CS, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;23(12):2222-32
   PubMed Web of Science ®Google Scholar
• Laubach JP, Voorhees PM, Hassoun H, et al. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol 2014;7(1):97-111
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11(16):5984-92
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140(1):36-45
   PubMed Web of Science ®Google Scholar